Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library
Herceptin® (trastuzumab) for HER2+ Cancer
Trastuzumab in the Treatment of Breast Cancer | SpringerLink
Schematic representation of the mechanism of action of trastuzumab... | Download Scientific Diagram
Pertuzumab and trastuzumab: the rationale way to synergy
General mechanisms of resistance to trastuzumab: presence of signaling... | Download Scientific Diagram
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer
Trastuzumab emtansine: mechanisms of action and drug resistance | Breast Cancer Research | Full Text
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Herceptin® (trastuzumab) for HER2+ Cancer
a) Summary of the proposed mechanism(s) of Trastuzumab action. The... | Download Scientific Diagram
Cancers | Free Full-Text | The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer | HTML
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Oncotarget
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer | British Journal of Cancer
TDM 1 Trastuzumab emtansine PreClinical and Early Clinical
IJMS | Free Full-Text | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer | HTML
Part:BBa K1694005 - parts.igem.org
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer - Annals of Oncology
Herceptin® (trastuzumab) for HER2+ Cancer
Trastuzumab
Pertuzumab and Its Accelerated Approval: Evolving Treatment Paradigms and New Challenges in the Management of HER2-Positive Breast Cancer
Trastuzumab (Herceptin) | American Journal of Neuroradiology
Mechanism of action of T-DM1 Notes: (1) Trastuzumab retains all of its... | Download Scientific Diagram
References in Evolving novel anti-HER2 strategies - The Lancet Oncology